EFG PH20 SC

Biologic

Argenx

EFG PH20 SC is one of 12 biologic programs targeting Idiopathic Inflammatory Myopathy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Inflammatory MyopathyActive, not recruiting

Idiopathic Inflammatory MyopathyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Idiopathic Inflammatory Myopathy

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Phase 3

1 2

Vyvgart

Argenx

Phase 3

1 3

Fabhalta

Medrol

1 5

Interleukin 2

EEssen Biotech

Phase 2

2 6

Mesnex

BBaxter Healthcare Corporation

Phase 1

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 8

Rituxan

Pfizer

Phase 1

1 9

GC012F

GGracell Biotechnologies (Shanghai) Co., Ltd.

Phase 1

1 10

G-CSF

AArog Pharmaceuticals, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Active, not recruiting

Idiopathic Inflammatory Myopathy

NCT05523167

Clinical

Trials by Indication[1]

Idiopathic Inflammatory Myopathy1 trial

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Active, not recruiting· Argenx logo

Argenx·Phase 2/3·NCT05523167·265 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EFG PH20 SC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EFG PH20 SC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EFG PH20 SC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Argenx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: Argenx

EFG PH20 SC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Idiopathic Inflammatory Myopathy1 trial

References

Drug Info

Quick Facts

Related News